CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | anti-HIV-1 agent |
|
Accession: | CHEBI:64947
|
browse the term
|
Definition: | An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus. |
Synonyms: | related_synonym: | anti-HIV-1 agents; anti-HTLV-III agent; anti-HTLV-III agents; anti-LAV agent; anti-LAV agents |
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases export decreases export |
ISO |
[Estradiol results in decreased activity of ABCG2 protein] which results in increased uptake of abacavir; [isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate results in decreased activity of ABCG2 protein] which results in increased uptake of abacavir 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of abacavir]; Elacridar inhibits the reaction [ABCG2 protein results in decreased export of abacavir]; Elacridar inhibits the reaction [ABCG2 protein results in increased export of abacavir]; Nelfinavir inhibits the reaction [ABCG2 protein results in increased export of abacavir]; pluronic block copolymer p85 inhibits the reaction [ABCG2 protein results in increased export of abacavir] |
CTD |
PMID:17437964 PMID:19056916 PMID:25844889 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
abacavir binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
abacavir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
abacavir results in increased expression of CRP protein |
CTD |
PMID:19891054 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
abacavir results in decreased expression of EYA1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
abacavir results in increased expression of FGF8 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Foxc2 |
forkhead box C2 |
decreases expression |
ISO |
abacavir results in decreased expression of FOXC2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
abacavir results in increased expression of GFAP protein |
CTD |
PMID:19358275 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Hoxb7 |
homeo box B7 |
increases expression |
ISO |
abacavir results in increased expression of HOXB7 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:84,135,224...84,138,642
Ensembl chr10:84,135,116...84,138,637
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
abacavir results in increased expression of HOXB9 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:84,119,772...84,124,963
Ensembl chr10:84,119,884...84,123,390
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IFNG protein |
CTD |
PMID:23541086 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IL13 protein |
CTD |
PMID:23541086 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il4 |
interleukin 4 |
affects response to substance |
ISO |
IL4 protein affects the susceptibility to abacavir |
CTD |
PMID:15867870 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
abacavir results in decreased expression of MEOX1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
abacavir results in decreased expression of MESP2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:141,550,633...141,553,239
Ensembl chr 1:141,550,633...141,553,230
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
abacavir results in increased expression of MMP9 protein |
CTD |
PMID:19891054 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
increases expression |
ISO |
abacavir results in increased expression of MPO protein |
CTD |
PMID:19891054 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Neurog2 |
neurogenin 2 |
increases expression |
ISO |
abacavir results in increased expression of NEUROG2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 2:231,962,517...231,963,441
Ensembl chr 2:231,962,517...231,963,308
|
|
G |
Olig3 |
oligodendrocyte transcription factor 3 |
increases expression |
ISO |
abacavir results in increased expression of OLIG3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:14,797,766...14,799,835
Ensembl chr 1:14,797,766...14,799,835
|
|
G |
Pax3 |
paired box 3 |
decreases expression |
ISO |
abacavir results in decreased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:84,004,004...84,101,226
Ensembl chr 9:84,005,183...84,101,172
|
|
G |
Pax6 |
paired box 6 |
increases expression |
ISO |
abacavir results in increased expression of PAX6 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
[Quinine results in decreased activity of SLC22A1] which results in decreased uptake of abacavir |
CTD |
PMID:25844889 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Syp |
synaptophysin |
increases expression |
ISO |
abacavir results in increased expression of SYP protein |
CTD |
PMID:19358275 |
|
NCBI chr X:15,694,699...15,709,244
Ensembl chr X:15,695,566...15,707,436
|
|
G |
Tcf15 |
transcription factor 15 |
decreases expression |
ISO |
abacavir results in decreased expression of TCF15 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:147,643,250...147,649,511
Ensembl chr 3:147,643,250...147,649,504
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
abacavir results in decreased activity of TERT protein |
CTD |
PMID:19358275 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of TNF protein |
CTD |
PMID:23541086 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
abacavir results in increased expression of UCP1 mRNA |
CTD |
PMID:14518702 |
|
NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
|
|
G |
Uncx |
UNC homeobox |
decreases expression |
ISO |
abacavir results in decreased expression of UNCX mRNA |
CTD |
PMID:31711903 |
|
NCBI chr12:17,182,158...17,186,679
Ensembl chr12:17,182,163...17,186,679
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions affects transport |
EXP |
Calcitriol promotes the reaction [ABCB4 protein affects the transport of adefovir] |
CTD |
PMID:21240898 PMID:21341280 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
affects abundance increases export |
ISO |
ABCC4 protein affects the abundance of adefovir ABCC4 protein results in increased export of adefovir |
CTD |
PMID:18364470 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
B2m |
beta-2 microglobulin |
increases secretion |
EXP |
adefovir results in increased secretion of B2M protein |
CTD |
PMID:27742868 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Calb1 |
calbindin 1 |
increases secretion |
EXP |
adefovir results in increased secretion of CALB1 protein |
CTD |
PMID:27742868 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
adefovir results in decreased activity of CYP2C9 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases secretion |
EXP |
adefovir results in increased secretion of HAVCR1 protein |
CTD |
PMID:27742868 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Lcn2 |
lipocalin 2 |
increases secretion |
EXP |
adefovir results in increased secretion of LCN2 protein |
CTD |
PMID:27742868 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Mmut |
methylmalonyl-CoA mutase |
affects expression increases expression |
ISO |
adefovir affects the expression of MMUT mRNA mutant form; adefovir affects the expression of MMUT protein mutant form adefovir results in increased expression of MMUT mRNA; adefovir results in increased expression of MMUT protein |
CTD |
PMID:19199343 PMID:19427250 |
|
NCBI chr 9:23,323,934...23,352,144
Ensembl chr 9:23,323,936...23,352,668
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases uptake affects response to substance multiple interactions increases response to substance |
EXP ISO |
SLC22A6 protein results in increased uptake of adefovir SLC22A6 protein affects the susceptibility to adefovir adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to adefovir]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein affects the susceptibility to adefovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to adefovir |
CTD |
PMID:16857889 PMID:21244849 PMID:23856525 PMID:25448811 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases response to substance |
ISO |
SLC22A8 protein results in increased susceptibility to adefovir |
CTD |
PMID:25448811 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases secretion |
EXP |
adefovir results in increased secretion of SPP1 protein |
CTD |
PMID:27742868 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects activity |
ISO |
adefovir dipivoxil affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ak4 |
adenylate kinase 4 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:120,250,318...120,309,153
Ensembl chr 5:120,250,616...120,305,897
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of AKR1C2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425 Ensembl chr 1:259,641,676...259,674,425
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Als2cl |
ALS2 C-terminal like |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ALS2CL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:119,156,081...119,176,680
Ensembl chr 8:119,160,731...119,174,830
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of ASNS mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ATAD2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:97,984,754...98,027,379
Ensembl chr 7:97,984,862...98,026,052
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ATF3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AURKB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AXL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of BAX mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bend5 |
BEN domain containing 5 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of BEND5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:131,257,127...131,312,335
Ensembl chr 5:131,257,127...131,312,335
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of BMF mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of BTG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Ccne2 |
cyclin E2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CCNE2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CDK6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CDKN1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CMBL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:84,645,084...84,666,836
Ensembl chr 2:84,645,084...84,666,835
|
|
G |
Coch |
cochlin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of COCH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of CTSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:151,918,514...151,949,979
Ensembl chr 1:151,918,571...151,949,983
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CYP1B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
adefovir dipivoxil results in decreased activity of CYP2C9 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
adefovir dipivoxil results in decreased activity of CYP3A4 protein |
CTD |
PMID:17162464 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DDB2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:80,030,437...80,052,984
Ensembl chr 3:80,030,437...80,052,953
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DGKA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:3,143,826...3,170,764
Ensembl chr 7:3,143,827...3,170,146
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DLGAP5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:24,167,484...24,199,417
Ensembl chr15:24,167,486...24,199,341
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of DLX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:58,164,931...58,169,521
Ensembl chr 3:58,164,931...58,169,521
|
|
G |
Dnai3 |
dynein axonemal intermediate chain 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DNAI3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:251,912,432...251,970,699
Ensembl chr 2:251,912,368...251,970,768
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DPYSL3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:37,716,371...37,819,347
Ensembl chr18:37,716,143...37,819,097
|
|
G |
Efna1 |
ephrin A1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of EFNA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:19,619,947...19,655,381
Ensembl chr15:19,619,973...19,655,381
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of FAS mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fbxo22 |
F-box protein 22 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:59,770,032...59,786,061
Ensembl chr 8:59,769,994...59,786,065
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GABARAPL1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GADD45A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GALNT16 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:104,069,853...104,250,177
Ensembl chr 6:104,068,547...104,250,174
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GCNT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:76,449,078...76,459,431
Ensembl chr 8:76,449,081...76,452,554
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GOT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpr87 |
G protein-coupled receptor 87 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GPR87 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:149,398,949...149,418,041
Ensembl chr 2:149,398,949...149,417,212
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of H1-2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:43,638,938...43,640,445
Ensembl chr17:43,639,749...43,640,387
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of HMOX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of HSPA1B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of NOS2 protein]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:9354585 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il19 |
interleukin 19 |
increases secretion |
ISO |
adefovir dipivoxil results in increased secretion of IL19 protein |
CTD |
PMID:24714768 |
|
NCBI chr13:47,663,592...47,677,869
Ensembl chr13:47,664,080...47,670,407
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of KAT6B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:2,811,933...2,966,833
Ensembl chr15:2,813,537...2,966,576
|
|
G |
Kdm3a |
lysine demethylase 3A |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of KDM3A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:99,503,160...99,547,315
Ensembl chr 4:99,503,176...99,546,905
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of KRT15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:88,046,803...88,050,622
Ensembl chr10:88,046,803...88,050,622
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of LAMA3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:3,704,866...3,941,215
Ensembl chr18:3,705,916...3,940,838
|
|
G |
Lcn2 |
lipocalin 2 |
increases secretion |
ISO |
adefovir dipivoxil results in increased secretion of LCN2 protein |
CTD |
PMID:24714768 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of MAP3K8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:56,109,403...56,129,925
Ensembl chr17:56,109,549...56,129,919
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of MXI1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:274,030,748...274,090,071
Ensembl chr 1:274,030,978...274,090,071
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NCAPD2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:157,682,855...157,705,903
Ensembl chr 4:157,683,077...157,704,596
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:15,866,235...15,881,284
Ensembl chr17:15,866,237...15,881,327
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of NOS2 protein]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:9354585 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of NQO1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of NREP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:26,183,753...26,212,796
Ensembl chr18:26,185,259...26,211,445
|
|
G |
Ntpcr |
nucleoside-triphosphatase, cancer-related |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NTPCR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:58,565,576...58,579,276
Ensembl chr19:58,565,576...58,579,265
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of P4HA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
Pank1 |
pantothenate kinase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PANK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:253,115,400...253,189,643
Ensembl chr 1:253,119,112...253,185,533
|
|
G |
Pdia5 |
protein disulfide isomerase family A, member 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:68,493,035...68,578,999
Ensembl chr11:68,493,035...68,578,995
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PDLIM1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:259,308,326...259,357,006
Ensembl chr 1:259,308,296...259,357,056
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
adefovir dipivoxil binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:52,588,917...52,592,002
Ensembl chr13:52,588,917...52,592,001
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PIDD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:214,418,751...214,423,959
Ensembl chr 1:214,419,240...214,423,881
|
|
G |
Pir |
pirin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:31,852,322...31,968,152
Ensembl chr X:31,852,323...31,968,152
|
|
G |
Plec |
plectin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PLEC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:117,230,319...117,291,859
Ensembl chr 7:117,230,319...117,289,961
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PMAIP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects activity |
ISO |
adefovir dipivoxil affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PPM1D mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:72,909,550...72,945,884
Ensembl chr10:72,909,550...72,945,884
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PRC1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:142,087,181...142,108,746
Ensembl chr 1:142,087,208...142,108,746
|
|
G |
Prdm1 |
PR/SET domain 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PRDM1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
|
|
G |
Prkab2 |
protein kinase AMP-activated non-catalytic subunit beta 2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PRKAB2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:199,831,990...199,847,623
Ensembl chr 2:199,831,990...199,847,629
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PSAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:233,124,089...233,145,941
Ensembl chr 1:233,124,092...233,145,941
|
|
G |
Rara |
retinoic acid receptor, alpha |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of RARA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rps27l |
ribosomal protein S27-like |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of RPS27L mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:72,741,155...72,746,090
Ensembl chr 8:72,741,155...72,746,090
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of RRM2B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
|
|
G |
Serpinb5 |
serpin family B member 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SERPINB5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:26,903,052...26,923,250
Ensembl chr13:26,903,052...26,923,250
|
|
G |
Sesn1 |
sestrin 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:46,667,116...46,758,306
Ensembl chr20:46,667,121...46,758,305
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SFN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
|
|
G |
Sh3tc1 |
SH3 domain and tetratricopeptide repeats 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SH3TC1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:80,184,814...80,229,207
Ensembl chr14:80,195,715...80,229,214
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:119,014,620...119,052,531
Ensembl chr 3:119,014,620...119,052,531
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:136,669,674...136,703,702
Ensembl chr 5:136,669,674...136,703,697
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Smap1 |
small ArfGAP 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SMAP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:30,068,888...30,161,753
Ensembl chr 9:30,068,659...30,161,578
|
|
G |
Sulf2 |
sulfatase 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SULF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:162,791,349...162,872,984
Ensembl chr 3:162,791,355...162,872,831
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
adefovir dipivoxil binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Tigar |
TP53 induced glycolysis regulatory phosphatase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TIGAR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:159,635,145...159,654,108
Ensembl chr 4:159,635,153...159,654,063
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:157,316,293...157,342,979
Ensembl chr 2:157,316,266...157,341,469
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TNFSF9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:9,909,942...9,912,276
Ensembl chr 9:9,909,948...9,912,276
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
adefovir dipivoxil affects the activity of TP53 protein |
CTD |
PMID:25596134 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TP53INP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:24,402,895...24,419,651
Ensembl chr 5:24,410,863...24,416,888
|
|
G |
Trafd1 |
TRAF type zinc finger domain containing 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:40,695,520...40,709,438
Ensembl chr12:40,695,520...40,709,462
|
|
G |
Triap1 |
TP53 regulated inhibitor of apoptosis 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TRIAP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:46,987,404...46,989,906
Ensembl chr12:46,987,404...46,989,897 Ensembl chr12:46,987,404...46,989,897
|
|
G |
Ube2o |
ubiquitin-conjugating enzyme E2O |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of UBE2O mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:105,505,721...105,553,167
Ensembl chr10:105,506,955...105,552,986
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of YARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:147,375,350...147,403,578
Ensembl chr 5:147,375,350...147,403,571
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ZMAT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:118,715,229...118,746,109
Ensembl chr 2:118,721,334...118,745,766
|
|
|
G |
Ar |
androgen receptor |
increases activity |
ISO |
alsterpaullone analog results in increased activity of AR protein |
CTD |
PMID:21111724 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
alsterpaullone inhibits the reaction [Colchicine results in increased activity of CASP3 protein] |
CTD |
PMID:20300959 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
alsterpaullone results in decreased activity of CDK2 protein |
CTD |
PMID:12534346 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity |
ISO |
alsterpaullone results in decreased activity of GSK3B protein |
CTD |
PMID:12534346 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
alsterpaullone results in decreased activity of LCK protein |
CTD |
PMID:12534346 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Tp53 |
tumor protein p53 |
affects localization multiple interactions |
ISO |
alsterpaullone affects the localization of TP53 protein alsterpaullone results in decreased degradation of and results in increased expression of TP53 protein |
CTD |
PMID:16055726 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
bryostatin 1 results in increased expression of BIRC3 mRNA |
CTD |
PMID:14527959 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Cd22 |
CD22 molecule |
increases expression |
ISO |
bryostatin 1 results in increased expression of CD22 protein |
CTD |
PMID:10741703 |
|
NCBI chr 1:89,313,475...89,329,902
Ensembl chr 1:89,314,558...89,329,418
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] |
CTD |
PMID:10516758 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
bryostatin 1 results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
bryostatin 1 analog results in decreased expression of IL10 mRNA; bryostatin 1 results in decreased expression of IL10 mRNA |
CTD |
PMID:15614042 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
decreases expression increases expression |
ISO |
bryostatin 1 analog results in decreased expression of IL12B mRNA bryostatin 1 results in increased expression of IL12B mRNA |
CTD |
PMID:15614042 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Itgax |
integrin subunit alpha X |
increases expression |
ISO |
bryostatin 1 results in increased expression of ITGAX protein |
CTD |
PMID:10741703 |
|
NCBI chr 1:199,555,560...199,576,948
Ensembl chr 1:199,555,722...199,576,932
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCA protein bryostatin 1 results in decreased expression of PRKCA protein |
CTD |
PMID:8892972 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein; [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein alternative form bryostatin 1 results in decreased expression of PRKCB protein; bryostatin 1 results in decreased expression of PRKCB protein alternative form |
CTD |
PMID:8892972 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCG protein bryostatin 1 results in decreased expression of PRKCG protein |
CTD |
PMID:8892972 |
|
NCBI chr 1:64,407,098...64,433,698
Ensembl chr 1:64,407,114...64,433,636
|
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
Delavirdine results in decreased activity of CYP2C9 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
Delavirdine results in decreased activity of CYP2C19 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Didanosine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Hfe |
homeostatic iron regulator |
multiple interactions |
ISO |
HFE gene SNP affects the susceptibility to [Didanosine co-treated with Stavudine] |
CTD |
PMID:16847405 |
|
NCBI chr17:43,661,276...43,669,327
Ensembl chr17:43,661,222...43,669,985
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression multiple interactions |
ISO |
Didanosine results in decreased expression of COX2 mRNA tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA] |
CTD |
PMID:16940060 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Didanosine |
CTD |
PMID:19164483 |
|
NCBI chr20:30,289,527...30,327,343
Ensembl chr20:30,287,424...30,327,361
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] efavirenz results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression decreases secretion |
ISO |
efavirenz results in decreased expression of ADIPOQ mRNA efavirenz results in decreased secretion of ADIPOQ protein |
CTD |
PMID:21619898 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Alb |
albumin |
affects binding |
ISO |
efavirenz binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases response to substance increases expression |
ISO |
BCL2L11 protein results in increased susceptibility to efavirenz metabolite efavirenz metabolite results in increased expression of BCL2L11 mRNA; efavirenz metabolite results in increased expression of BCL2L11 protein; efavirenz results in increased expression of BCL2L11 mRNA; efavirenz results in increased expression of BCL2L11 protein |
CTD |
PMID:21958719 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
efavirenz affects the localization of CANX protein |
CTD |
PMID:28940366 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
efavirenz metabolite results in increased cleavage of and results in increased activity of CASP3 protein; efavirenz results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:21958719 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
efavirenz results in increased secretion of CCL2 protein |
CTD |
PMID:21619898 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
efavirenz results in decreased expression of CEBPA mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects metabolic processing decreases activity multiple interactions increases metabolic processing |
ISO |
CYP2B6 gene polymorphism affects the metabolism of efavirenz; CYP2B6 protein affects the metabolism of efavirenz efavirenz results in decreased activity of CYP2B6 protein [efavirenz results in decreased activity of CYP2B6 protein] which results in decreased metabolism of Bupropion; [efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA CYP2B6 protein results in increased metabolism of efavirenz |
CTD |
PMID:15622315 PMID:15769884 PMID:17041008 PMID:17559344 PMID:26599973 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
efavirenz results in decreased activity of CYP2C9 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
efavirenz results in decreased activity of CYP2C19 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity increases expression increases activity |
ISO |
efavirenz results in decreased activity of CYP3A4 protein efavirenz results in increased expression of CYP3A4 mRNA efavirenz results in increased activity of CYP3A4 protein |
CTD |
PMID:15980690 PMID:16837568 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
efavirenz results in increased expression of DDIT3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization |
ISO |
efavirenz affects the localization of DNM1L protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
efavirenz results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
ISO |
efavirenz results in increased expression of FIS1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
|
|
G |
Hgf |
hepatocyte growth factor |
increases secretion |
ISO |
efavirenz results in increased secretion of HGF protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
efavirenz results in increased secretion of IL6 protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of JUN protein; efavirenz results in increased phosphorylation of JUN protein |
CTD |
PMID:21958719 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
efavirenz results in decreased expression of LEP mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions increases expression increases response to substance |
ISO |
efavirenz results in increased expression of and affects the localization of LONP1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [efavirenz results in increased expression of LONP1 mRNA] LONP1 protein results in increased susceptibility to efavirenz |
CTD |
PMID:28940366 |
|
NCBI chr 9:10,428,853...10,441,180
Ensembl chr 9:10,428,853...10,441,177
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
efavirenz results in decreased expression of LPL mRNA |
CTD |
PMID:21619898 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of MAP3K5 protein; efavirenz results in increased phosphorylation of MAP3K5 protein |
CTD |
PMID:21958719 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [efavirenz metabolite results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [efavirenz results in increased phosphorylation of MAPK8 protein] efavirenz metabolite results in increased phosphorylation of MAPK8 protein; efavirenz results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:21958719 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression |
ISO |
efavirenz results in increased expression of MFN2 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
efavirenz results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity |
ISO EXP |
[efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 PMID:27732639 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
ISO |
efavirenz results in increased expression of OPA1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
efavirenz results in decreased expression of PPARG mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
increases expression |
ISO |
efavirenz results in increased expression of RMDN3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 3:110,943,843...110,964,449
Ensembl chr 3:110,943,826...110,964,452
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion |
ISO |
efavirenz results in increased secretion of SERPINE1 protein |
CTD |
PMID:21619898 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein |
CTD |
PMID:16030158 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
efavirenz results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21619898 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tg |
thyroglobulin |
increases expression |
ISO |
efavirenz results in increased expression of TG mRNA; efavirenz results in increased expression of TG protein |
CTD |
PMID:16030158 |
|
NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
efavirenz results in increased expression of TPO mRNA; efavirenz results in increased expression of TPO protein |
CTD |
PMID:16030158 |
|
NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein; efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]; sodium perchlorate inhibits the reaction [efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]] |
CTD |
PMID:16030158 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
efavirenz results in increased expression of TSHR mRNA |
CTD |
PMID:16030158 |
|
NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Emtricitabine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions affects binding |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Emtricitabine Emtricitabine binds to DCK protein |
CTD |
PMID:17530837 |
|
NCBI chr14:20,935,442...20,952,939
Ensembl chr14:20,935,369...20,953,095
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression multiple interactions |
ISO |
Emtricitabine results in decreased expression of PRKN protein [Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
fangchinoline results in increased expression of ATF4 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of ATF4 protein] |
CTD |
PMID:28754437 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
fangchinoline results in decreased expression of BIRC5 mRNA; fangchinoline results in decreased expression of BIRC5 protein |
CTD |
PMID:28754437 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
fangchinoline results in increased cleavage of CASP3 protein |
CTD |
PMID:28754437 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
fangchinoline results in increased cleavage of CASP8 protein |
CTD |
PMID:28754437 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
fangchinoline results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of DDIT3 protein] |
CTD |
PMID:28754437 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
fangchinoline results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of HSPA5 protein] |
CTD |
PMID:28754437 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
fangchinoline results in increased cleavage of PARP1 protein |
CTD |
PMID:28754437 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ACADSB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ACSL6 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:39,654,771...39,717,592
Ensembl chr10:39,655,455...39,719,312
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Lamivudine results in decreased expression of ACTA2 protein |
CTD |
PMID:11738102 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Aebp1 |
AE binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of AEBP1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr14:86,101,253...86,111,323
Ensembl chr14:86,101,277...86,111,306
|
|
G |
Afap1 |
actin filament associated protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of AFAP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr14:79,923,132...80,035,096
Ensembl chr14:79,919,717...79,988,110
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Lamivudine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of AQP9 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ARPP21 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:120,323,895...120,492,790
Ensembl chr 8:120,323,897...120,446,507
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ASIC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:68,247,800...69,347,223
Ensembl chr10:68,248,655...68,517,564
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASNS mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:10,327,411...10,375,847
Ensembl chr 3:10,327,414...10,375,826
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATF3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:11706060 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5C1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr17:72,209,321...72,231,562
Ensembl chr17:72,209,373...72,394,271
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5G3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:60,811,218...60,813,903
Ensembl chr 3:60,811,210...60,813,869
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5J2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:11,191,799...11,198,369
Ensembl chr12:11,191,812...11,198,369
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5H mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:103,967,340...103,972,552
Ensembl chr10:103,967,312...103,972,668
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5J mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:24,286,806...24,294,419
Ensembl chr11:24,286,787...24,294,179
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5O mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:32,081,606...32,087,918
Ensembl chr11:32,081,574...32,088,002
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of BCL2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Lamivudine results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C1R mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:157,126,060...157,136,825
Ensembl chr 4:157,125,998...157,136,829
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of C3AR1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:155,681,767...155,691,240
Ensembl chr 4:155,684,029...155,690,869
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNA2 mRNA Lamivudine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNC mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CCND1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CCND2 mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CCND2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNE2 mRNA Lamivudine results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CD36 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CD44 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CD83 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CDK7 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:30,710,642...30,735,522
Ensembl chr 2:30,710,643...30,735,514
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CDKN1A mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:15784690 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CFD mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CIDEC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of CLCN3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Lamivudine results in decreased expression of COL3A1 protein |
CTD |
PMID:11738102 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COMT mRNA |
CTD |
PMID:15784690 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:62,298,358...62,309,765
Ensembl chr 8:62,298,358...62,309,765
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX5B mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:43,259,706...43,262,039
Ensembl chr 9:43,259,709...43,262,040
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:47,024,442...47,027,495
Ensembl chr12:47,024,442...47,027,495
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:74,723,177...74,735,650
Ensembl chr 7:74,723,179...74,735,650
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX7C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:14,699,878...14,701,903
Ensembl chr 2:14,699,882...14,701,903
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CPT1A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crat |
carnitine O-acetyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CRAT mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:8,967,984...8,981,959
Ensembl chr 3:8,968,417...8,981,362
|
|
G |
Cul7 |
cullin 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CUL7 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:16,629,491...16,643,527
Ensembl chr 9:16,629,401...16,643,182
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CYB5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Lamivudine |
CTD |
PMID:17530837 |
|
NCBI chr14:20,935,442...20,952,939
Ensembl chr14:20,935,369...20,953,095
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DCN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Lamivudine results in increased expression of DDIT3 mRNA [Zidovudine co-treated with Lamivudine] results in increased expression of DDIT3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DHFR mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DIABLO mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DLST mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:108,936,534...108,961,322
Ensembl chr 6:108,936,664...108,959,803
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DNAJA3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:11,059,701...11,085,186
Ensembl chr10:11,060,313...11,085,210
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of DUSP3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:89,904,578...89,918,296
Ensembl chr10:89,904,560...89,918,427
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ECHS1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ECI1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:13,797,573...13,810,918
Ensembl chr10:13,797,562...13,810,913
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases secretion |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of ELOVL3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:265,883,353...265,887,181
Ensembl chr 1:265,883,355...265,887,226
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ETV6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:167,754,684...167,992,370
Ensembl chr 4:167,754,525...167,992,168
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of FADS2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of FAIM mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:107,225,119...107,247,228
Ensembl chr 8:107,225,212...107,241,224 Ensembl chr 8:107,225,212...107,241,224
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of FASN mRNA |
CTD |
PMID:11741158 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fdxr |
ferredoxin reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FDXR mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:103,817,724...103,826,413
Ensembl chr10:103,817,704...103,826,448
|
|
G |
Fh |
fumarate hydratase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FH1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of G0S2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of G6PC1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of GANC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:112,173,907...112,226,886
Ensembl chr 3:112,173,907...112,226,023
|
|
G |
Gars |
glycyl-tRNA synthetase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of GARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GAS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Grhl2 |
grainyhead-like transcription factor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GRHL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:76,058,623...76,197,360
Ensembl chr 7:76,059,386...76,197,856
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of GUCY1B1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of HADH mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HADHA mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HAX1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:189,330,900...189,333,305
Ensembl chr 2:189,330,902...189,333,322
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of HCN1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:50,099,576...50,499,799
Ensembl chr 2:50,099,576...50,499,799
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HRK mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:44,008,879...44,029,211
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:200,756,557...200,762,492
Ensembl chr 2:200,585,748...200,762,492
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH3A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of IDH3G mRNA |
CTD |
PMID:18313992 |
|
NCBI chr X:156,999,803...157,008,735
Ensembl chr X:156,999,826...157,008,733
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Lamivudine results in increased expression of IFNG protein |
CTD |
PMID:16250037 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikzf4 |
IKAROS family zinc finger 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of IKZF4 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:3,061,422...3,098,142
Ensembl chr 7:3,061,469...3,074,359
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IL27RA mRNA |
CTD |
PMID:15784690 |
|
NCBI chr19:25,151,835...25,163,995
Ensembl chr19:25,149,897...25,164,086
|
|
G |
Inpp5e |
inositol polyphosphate-5-phosphatase E |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of INPP5E mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:3,843,307...3,856,154
Ensembl chr 3:3,843,307...3,855,981
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KCNG1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:165,020,230...165,040,966
Ensembl chr 3:165,020,230...165,039,707
|
|
G |
Kifc2 |
kinesin family member C2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of KIFC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:117,722,732...117,730,702
Ensembl chr 7:117,723,263...117,730,702
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KLF4 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klhl28 |
kelch-like family member 28 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of KLHL28 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:86,680,826...86,713,370
Ensembl chr 6:86,684,413...86,713,370
|
|
G |
Krt7 |
keratin 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KRT7 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:143,059,731...143,075,907
Ensembl chr 7:143,059,764...143,075,907
|
|
G |
Kynu |
kynureninase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KYNU mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:28,416,926...28,566,939
Ensembl chr 3:28,416,954...28,566,928
|
|
G |
Lamb3 |
laminin subunit beta 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of LAMB3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:112,031,614...112,073,187
Ensembl chr13:112,031,594...112,073,186
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of LAMC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEF1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of LPL mRNA [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of LPL mRNA; [Stavudine co-treated with Lamivudine] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of LPL mRNA |
CTD |
PMID:11741158 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Mars1 |
methionyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:70,585,011...70,602,425
Ensembl chr 7:70,585,013...70,602,310
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions increases expression |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine] affects the expression of ME1 mRNA Lamivudine results in increased expression of ME1 mRNA |
CTD |
PMID:11741158 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MFN1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MFN2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mgat4c |
MGAT4 family, member C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MGAT4C mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:43,249,369...44,024,278
Ensembl chr 7:44,009,069...44,024,456
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Lamivudine results in increased expression of MMP1 protein |
CTD |
PMID:15309715 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mrap |
melanocortin 2 receptor accessory protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of MRAP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:30,904,733...30,915,225
Ensembl chr11:30,904,733...30,915,225
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX1 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX3 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Mt-nd2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ND2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
|
|
G |
Mt-nd5 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ND5 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MTHFD2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Myod1 |
myogenic differentiation 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MYOD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NAP1L5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:89,149,314...89,152,511
Ensembl chr 4:89,149,317...89,151,184
|
|
G |
Ndufa4 |
NDUFA4, mitochondrial complex associated |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFA4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 4:38,233,680...38,240,848
Ensembl chr 4:38,233,680...38,240,848
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAB1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:192,044,209...192,057,644
Ensembl chr 1:192,044,216...192,057,612
|
|
G |
Ndufaf1 |
NADH:ubiquinone oxidoreductase complex assembly factor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAF1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:111,458,227...111,469,239
Ensembl chr 3:111,458,572...111,469,518
|
|
G |
Ndufb3 |
NADH:ubiquinone oxidoreductase subunit B3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:65,478,496...65,488,708
Ensembl chr 9:65,478,496...65,488,702
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB5 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:119,139,717...119,153,753
Ensembl chr 2:119,139,717...119,153,753
|
|
G |
Ndufb9 |
NADH:ubiquinone oxidoreductase subunit B9 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFB9 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:98,813,062...98,819,408
Ensembl chr 7:98,813,040...98,819,452
|
|
G |
Ndufc1 |
NADH:ubiquinone oxidoreductase subunit C1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFC1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:140,460,749...140,464,588
Ensembl chr 2:140,462,900...140,464,607
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFS1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:69,919,863...69,953,182
Ensembl chr 9:69,919,867...69,953,182
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NIBAN1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:68,949,665...69,101,600
Ensembl chr13:68,949,665...69,101,588
|
|
G |
Noct |
nocturnin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of NOCT mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:140,286,661...140,306,869
Ensembl chr 2:140,286,661...140,306,869
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases phosphorylation |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NPPA mRNA |
CTD |
PMID:11706060 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nup210 |
nucleoporin 210 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NUP210 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:122,643,952...122,741,322
Ensembl chr 4:122,644,135...122,741,110
|
|
G |
Nxnl2 |
nucleoredoxin-like 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NXNL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:14,053,896...14,058,642
Ensembl chr17:14,053,896...14,058,642
|
|
G |
Oaz3 |
ornithine decarboxylase antizyme 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of OAZ3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:195,675,925...195,678,859
Ensembl chr 2:195,676,048...195,678,848
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OGT mRNA |
CTD |
PMID:15784690 |
|
NCBI chr X:71,540,870...71,585,906
Ensembl chr X:71,528,988...71,585,908
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OPA1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OPRL1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:177,223,779...177,231,663
Ensembl chr 3:177,225,737...177,231,663
|
|
G |
Pcdh15 |
protocadherin related 15 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PCDH15 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:14,952,213...15,334,745
Ensembl chr20:14,952,213...15,334,745
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PCK2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr15:34,216,735...34,224,357
Ensembl chr15:34,216,833...34,224,193
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:70,632,778...70,713,736
Ensembl chr17:70,684,134...70,713,726
|
|
G |
Pgap6 |
post-glycosylphosphatidylinositol attachment to proteins 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PGAP6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:15,484,952...15,495,380
Ensembl chr10:15,484,795...15,495,377
|
|
G |
Phf6 |
PHD finger protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of PHF6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:158,698,353...158,739,855
Ensembl chr X:158,698,356...158,739,838 Ensembl chr X:158,698,356...158,739,838
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIDD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:214,418,751...214,423,959
Ensembl chr 1:214,419,240...214,423,881
|
|
G |
Piwil2 |
piwi-like RNA-mediated gene silencing 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PIWIL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr15:52,037,693...52,116,277
Ensembl chr15:52,037,693...52,116,001
|
|
G |
Porcn |
porcupine O-acyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PPN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:15,035,569...15,048,440
Ensembl chr X:15,035,569...15,048,440
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of POU5F1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PRDM1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PSAT1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:233,124,089...233,145,941
Ensembl chr 1:233,124,092...233,145,941
|
|
G |
Rabepk |
Rab9 effector protein with kelch motifs |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of RABEPK mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:13,845,352...13,865,843
Ensembl chr 3:13,845,361...13,865,843
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of RBL1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of RBL2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr19:17,300,088...17,346,865
Ensembl chr19:17,300,089...17,346,808
|
|
G |
Reep6 |
receptor accessory protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of REEP6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:12,240,059...12,246,814
Ensembl chr 7:12,240,060...12,246,729
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of H4C9 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:170,762,862...170,763,962
Ensembl chr 4:170,763,605...170,763,916
|
|
G |
Ripk2 |
receptor-interacting serine-threonine kinase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of RIPK2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:29,838,713...29,870,390
Ensembl chr 5:29,838,747...29,870,735
|
|
G |
Rnf151 |
ring finger protein 151 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of RNF151 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:14,083,538...14,088,011
Ensembl chr10:14,083,538...14,085,855
|
|
G |
Rpain |
RPA interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of RPAIN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:57,606,287...57,613,834
Ensembl chr10:57,606,650...57,613,747
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of S100A8 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SDHB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 5:159,484,378...159,505,063
Ensembl chr 5:159,484,370...159,505,064
|
|
G |
Serinc1 |
serine incorporator 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SERINC1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:38,966,016...38,985,056
Ensembl chr20:38,967,238...38,985,036
|
|
G |
Sfxn1 |
sideroflexin 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr17:11,046,588...11,082,219
Ensembl chr17:11,045,761...11,082,047
|
|
G |
Sfxn2 |
sideroflexin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:266,333,440...266,345,736
Ensembl chr 1:266,333,440...266,345,697
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:282,213,610...282,236,851
Ensembl chr 1:282,213,675...282,235,974
|
|
G |
Sgpp1 |
sphingosine-1-phosphate phosphatase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SGPP1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:98,675,324...98,696,492
Ensembl chr 6:98,675,326...98,695,988
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A4 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr14:104,582,884...104,612,417
Ensembl chr14:104,581,190...104,612,597
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A5 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:78,710,686...78,724,789
Ensembl chr 1:78,710,539...78,724,794
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases uptake |
ISO |
SLC22A1 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake |
ISO |
SLC22A2 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
increases uptake |
ISO |
SLC22A3 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc25a12 |
solute carrier family 25 member 12 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:57,881,951...57,998,214
Ensembl chr 3:57,882,370...57,957,346
|
|
G |
Slc25a15 |
solute carrier family 25 member 15 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A15 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:74,505,318...74,554,523
Ensembl chr16:74,531,564...74,554,529
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
multiple interactions |
ISO |
SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir] [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A19 mRNA |
CTD |
PMID:15951836 PMID:18313992 |
|
NCBI chr10:104,166,594...104,179,523
Ensembl chr10:104,166,598...104,179,523
|
|
G |
Slc25a2 |
solute carrier family 25 member 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr18:30,774,205...30,775,401
Ensembl chr18:30,774,205...30,775,401
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A20 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:117,455,308...117,476,762
Ensembl chr 8:117,455,262...117,476,734
|
|
G |
Slc25a29 |
solute carrier family 25 member 29 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A29 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:132,736,964...132,747,912
Ensembl chr 6:132,735,883...132,747,828
|
|
G |
Slc25a3 |
solute carrier family 25 member 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:31,816,601...31,824,064
Ensembl chr 7:31,816,602...31,824,071
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:49,266,903...49,270,698
Ensembl chr16:49,266,903...49,270,698
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions |
ISO |
Lamivudine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] |
CTD |
PMID:10772724 |
|
NCBI chr 1:142,948,942...142,992,410
Ensembl chr 1:142,950,540...142,992,615
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC31A1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:78,222,504...78,249,358
Ensembl chr 5:78,222,504...78,249,358
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC3A2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC40A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions increases expression |
ISO |
[Lamivudine co-treated with IFNA2 protein] results in increased expression of SLC6A4 mRNA; Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein Lamivudine results in increased expression of SLC6A4 mRNA |
CTD |
PMID:16476009 |
|
NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
|
|
G |
Spink5 |
serine peptidase inhibitor, Kazal type 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of SPINK5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr18:35,118,300...35,190,458
Ensembl chr18:35,121,967...35,191,069 Ensembl chr 1:35,121,967...35,191,069
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of STAR mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stc2 |
stanniocalcin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of STC2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr10:16,542,909...16,552,675
Ensembl chr10:16,542,882...16,553,295
|
|
G |
Sub1 |
SUB1 regulator of transcription |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SUB1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:62,019,902...62,034,704
Ensembl chr 2:62,022,567...62,034,628
|
|
G |
Tcea1 |
transcription elongation factor A1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TCEA1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:14,511,183...14,548,494
Ensembl chr 5:14,511,183...14,548,429
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Lamivudine results in decreased expression of TGFB1 protein |
CTD |
PMID:15309715 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Timm17b |
translocase of inner mitochondrial membrane 17b |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TIMM17B mRNA |
CTD |
PMID:18313992 |
|
NCBI chr X:15,441,369...15,448,452
Ensembl chr X:15,441,651...15,448,403
|
|
G |
Timm23 |
translocase of inner mitochondrial membrane 23 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TIMM23 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:8,324,038...8,350,067
Ensembl chr16:8,324,036...8,350,067
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
ISO |
Lamivudine results in decreased expression of TIMP1 protein |
CTD |
PMID:15309715 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TIMP2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
|
|
G |
Tk2 |
thymidine kinase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TK2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr19:917,203...939,236
Ensembl chr19:917,203...939,221
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TRIB3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Trim42 |
tripartite motif-containing 42 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TRIM42 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:105,205,041...105,226,541
Ensembl chr 8:105,204,993...105,226,588
|
|
G |
Twnk |
twinkle mtDNA helicase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TWNK mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:264,756,060...264,762,892
Ensembl chr 1:264,756,499...264,762,892
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TYMS mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TYRP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
G |
Uqcrb |
ubiquinol-cytochrome c reductase binding protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of UQCRB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:71,264,501...71,269,869
Ensembl chr 7:71,264,514...71,269,869 Ensembl chr 1:71,264,514...71,269,869
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of UQCRC1 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr 8:117,679,328...117,691,073
Ensembl chr 8:117,679,278...117,691,071
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of UQCRC2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:190,555,177...190,585,741
Ensembl chr 1:190,555,177...190,585,734
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VDAC1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VDR mRNA |
CTD |
PMID:11741158 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
G |
Vps4b |
vacuolar protein sorting 4 homolog B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VPS4B mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:26,825,261...26,850,460
Ensembl chr13:26,825,261...26,850,460
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of WARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 6:132,771,026...132,802,262
Ensembl chr 6:132,771,021...132,802,210
|
|
G |
Wnt10a |
Wnt family member 10A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of WNT10A mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 9:82,053,581...82,066,047
Ensembl chr 9:82,053,581...82,066,047
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of YARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:147,375,350...147,403,578
Ensembl chr 5:147,375,350...147,403,571
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Nevirapine results in increased expression of ABCB1A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of ADAMTS9 mRNA; Nevirapine results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:124,660,254...124,860,997
Ensembl chr 4:124,660,262...124,858,250
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ADGRF5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:20,091,121...20,195,706
Ensembl chr 9:20,091,099...20,195,566
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression increases secretion |
ISO |
Nevirapine results in increased expression of ADIPOQ mRNA Nevirapine results in increased secretion of ADIPOQ protein |
CTD |
PMID:21619898 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of AIF1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Nevirapine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
ISO |
Nevirapine results in increased expression of APOA1 protein |
CTD |
PMID:19667106 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Ar |
androgen receptor |
increases expression |
ISO |
Nevirapine results in increased expression of AR mRNA; Nevirapine results in increased expression of AR protein |
CTD |
PMID:19152342 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Armcx2 |
armadillo repeat containing, X-linked 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of ARMCX2 mRNA; Nevirapine results in decreased expression of ARMCX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:105,617,383...105,622,209
Ensembl chr X:105,617,385...105,622,156
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ARNT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CD36 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
Nevirapine results in increased expression of CEBPA mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
EXP |
Nevirapine results in increased expression of CES2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
increases expression |
ISO |
Nevirapine results in increased expression of CIITA |
CTD |
PMID:26626330 |
|
NCBI chr10:5,212,621...5,260,641
Ensembl chr10:5,213,350...5,260,608
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
decreases expression |
EXP |
Nevirapine results in decreased expression of CLEC4A1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:155,913,366...155,923,079
Ensembl chr 4:155,913,366...155,923,079
|
|
G |
Clec4m |
C-type lectin domain family 4 member M |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CD209B mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:2,817,633...2,826,303
Ensembl chr12:2,816,065...2,826,378
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of COTL1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:52,465,074...52,499,433
Ensembl chr19:52,465,087...52,499,433
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of CUX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:40,016,774...40,221,067
Ensembl chr12:40,018,937...40,219,291
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CYP2B1 mRNA; Nevirapine results in increased expression of CYP2B1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Nevirapine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Nevirapine results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects binding |
EXP |
Nevirapine binds to CYP2C11 protein |
CTD |
PMID:22793666 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects binding increases expression |
EXP |
Nevirapine binds to CYP3A23-3A1 protein Nevirapine results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:22793666 PMID:23947594 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects binding |
ISO |
Nevirapine binds to CYP3A4 protein |
CTD |
PMID:22793666 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
Nevirapine results in increased expression of CYP3A9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CYP4B1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:134,508,728...134,526,103
Ensembl chr 5:134,508,730...134,526,089
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of DAPK1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of DBP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:101,687,896...101,692,845
Ensembl chr 1:101,687,855...101,692,846
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of DDHD1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:19,963,639...20,032,263
Ensembl chr15:19,965,187...20,032,191
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
increases expression |
EXP |
Nevirapine results in increased expression of DIP2A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:13,044,056...13,127,971
Ensembl chr20:13,044,104...13,127,487
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of DNAJB5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:58,393,197...58,402,162
Ensembl chr 5:58,393,233...58,401,870
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
increases expression |
EXP |
Nevirapine results in increased expression of EDEM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:140,886,644...140,918,654
Ensembl chr 4:140,886,545...140,915,779
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Nevirapine results in decreased expression of EGF mRNA |
CTD |
PMID:19152342 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Nevirapine results in decreased expression of EGFR mRNA |
CTD |
PMID:19152342 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
decreases expression |
EXP |
Nevirapine results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:117,314,935...117,666,408
Ensembl chr 9:117,538,009...117,666,410
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ESM1 mRNA; Nevirapine results in increased expression of ESM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:45,104,392...45,113,130
Ensembl chr 2:45,104,305...45,113,131
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
increases expression |
EXP |
Nevirapine results in increased expression of FAM107A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:18,399,145...18,415,959
Ensembl chr15:18,399,515...18,415,965
|
|
G |
Fibin |
fin bud initiation factor homolog |
increases expression |
EXP |
Nevirapine results in increased expression of FIBIN mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:101,545,207...101,547,478
Ensembl chr 3:101,545,208...101,547,478
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of FKBP5 mRNA; Nevirapine results in increased expression of FKBP5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of FMO1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
EXP |
Nevirapine results in increased expression of GADD45B mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GLUL mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases glutathionylation |
ISO |
GSTA1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases glutathionylation |
ISO |
GSTM1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases glutathionylation |
ISO |
GSTP1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gzma |
granzyme A |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GZMA mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
Gzmf |
granzyme F |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GZMF mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:35,182,405...35,195,725
Ensembl chr15:35,184,364...35,195,725
|
|
G |
Hao2 |
hydroxyacid oxidase 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HAO2 mRNA; Nevirapine results in decreased expression of HAO2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:200,785,492...200,808,868
Ensembl chr 2:200,778,122...200,808,857
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HDC mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:119,057,524...119,075,599
Ensembl chr 3:119,057,517...119,075,619
|
|
G |
Hgf |
hepatocyte growth factor |
decreases secretion |
ISO |
Nevirapine results in decreased secretion of HGF protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of HMGCS2 mRNA; Nevirapine results in increased expression of HMGCS2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of HPGD mRNA |
CTD |
PMID:23947594 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HSD17B2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO EXP |
Nevirapine results in increased expression of IFNG protein |
CTD |
PMID:23947594 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igh-6 |
immunoglobulin heavy chain 6 |
increases expression |
EXP |
Nevirapine results in increased expression of IGH-6 mRNA |
CTD |
PMID:23947594 |
|
Ensembl chr 6:138,092,131...138,093,643
|
|
G |
Il22ra2 |
interleukin 22 receptor subunit alpha 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of IL22RA2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:15,084,136...15,107,423
Ensembl chr 1:15,093,599...15,106,954
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
ISO |
Nevirapine results in decreased secretion of IL6 protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhbe |
inhibin subunit beta E |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of INHBE mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Inmt |
indolethylamine N-methyltransferase |
increases expression |
EXP |
Nevirapine results in increased expression of INMT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:85,381,907...85,386,203
Ensembl chr 4:85,381,889...85,386,231
|
|
G |
Insig2 |
insulin induced gene 2 |
increases expression |
EXP |
Nevirapine results in increased expression of INSIG2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:37,264,818...37,292,718
Ensembl chr13:37,266,312...37,287,458
|
|
G |
Irgm |
immunity-related GTPase M |
decreases expression |
EXP |
Nevirapine results in decreased expression of IRGM mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:34,213,885...34,221,968
Ensembl chr10:34,213,936...34,221,928
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
EXP |
Nevirapine results in increased expression of ITPR1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
|
|
G |
Klf15 |
Kruppel-like factor 15 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of KLF15 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:122,364,688...122,377,690
Ensembl chr 4:122,365,093...122,377,659
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Nevirapine results in increased expression of KRT18 protein |
CTD |
PMID:19152342 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt23 |
keratin 23 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of KRT23 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:87,391,623...87,407,634
Ensembl chr10:87,391,623...87,407,634
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases expression |
ISO |
Nevirapine results in increased expression of LCAT protein |
CTD |
PMID:19667106 |
|
NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Nevirapine results in increased expression of LEP mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lifr |
LIF receptor subunit alpha |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LIFR mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
|
|
G |
Lilrb3l |
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3-like |
decreases expression |
EXP |
Nevirapine results in decreased expression of LILRB3L mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:63,759,638...63,849,278
Ensembl chr 1:63,759,638...64,013,289
|
|
G |
Lipg |
lipase G, endothelial type |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of LIPG mRNA; Nevirapine results in decreased expression of LIPG mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LPIN1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
Nevirapine results in increased expression of LPL mRNA |
CTD |
PMID:21619898 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LRG1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:10,952,424...10,954,664
Ensembl chr 9:10,952,374...10,954,681
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
EXP |
Nevirapine results in decreased expression of LY86 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:28,104,535...28,191,447
Ensembl chr17:28,104,589...28,191,436
|
|
G |
Meox2 |
mesenchyme homeobox 2 |
increases expression |
EXP |
Nevirapine results in increased expression of MEOX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:56,625,768...56,689,195
Ensembl chr 6:56,625,650...56,689,238
|
|
G |
Mgp |
matrix Gla protein |
increases expression |
EXP |
Nevirapine results in increased expression of MGP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:170,856,783...170,860,105
Ensembl chr 4:170,856,751...170,860,225
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of MRC1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Ms4a7 |
membrane spanning 4-domains A7 |
decreases expression |
EXP |
Nevirapine results in decreased expression of MS4A7 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:227,490,777...227,506,819
Ensembl chr 1:227,490,777...227,506,822
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of NAMPT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
|
|
G |
Ndufaf4 |
NADH:ubiquinone oxidoreductase complex assembly factor 4 |
increases expression |
EXP |
Nevirapine results in increased expression of NDUFAF4 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:39,251,370...39,256,542
Ensembl chr 5:39,251,337...39,257,512
|
|
G |
Nlrc5 |
NLR family, CARD domain containing 5 |
increases expression |
ISO |
Nevirapine results in increased expression of NLRC5 |
CTD |
PMID:26626330 |
|
NCBI chr19:10,904,381...11,006,202
Ensembl chr19:10,905,542...10,976,396
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NPAS2 mRNA; Nevirapine results in decreased expression of NPAS2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:45,901,262...46,081,880
Ensembl chr 9:45,901,741...46,081,880
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
increases expression |
EXP |
Nevirapine results in increased expression of NPTX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:12,014,638...12,025,547
Ensembl chr12:12,013,911...12,025,549
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NR1D1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:86,683,875...86,690,815
Ensembl chr10:86,683,875...86,690,815
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Nevirapine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Nevirapine results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NREP mRNA; Nevirapine results in decreased expression of NREP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:26,183,753...26,212,796
Ensembl chr18:26,185,259...26,211,445
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases expression |
EXP |
Nevirapine results in decreased expression of P2RX7 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Pcp4l1 |
Purkinje cell protein 4-like 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of PCP4L1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:89,542,377...89,565,920
Ensembl chr13:89,542,378...89,565,813
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PDK4 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression |
EXP |
Nevirapine results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr14:83,559,397...83,572,481
Ensembl chr14:83,560,541...83,572,473
|
|
G |
Pir |
pirin |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PIR mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:31,852,322...31,968,152
Ensembl chr X:31,852,323...31,968,152
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PNPLA2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of POR mRNA; Nevirapine results in increased expression of POR mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Nevirapine results in increased expression of PPARG mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PPP2R2B mRNA; Nevirapine results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:36,985,709...37,421,383
Ensembl chr18:36,985,714...37,245,809
|
|
G |
Prf1 |
perforin 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PRF1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PYCR1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:109,817,300...109,822,218
Ensembl chr10:109,818,177...109,821,807
|
|
G |
Rbm3 |
RNA binding motif protein 3 |
increases expression |
EXP |
Nevirapine results in increased expression of RBM3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:15,098,880...15,102,344
Ensembl chr X:15,098,904...15,102,340
|
|
G |
Retreg1 |
reticulophagy regulator 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of RETREG1 mRNA; Nevirapine results in increased expression of RETREG1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:78,391,921...78,401,569
Ensembl chr 2:78,391,921...78,399,987
|
|
G |
Rhbdd2 |
rhomboid domain containing 2 |
increases expression |
EXP |
Nevirapine results in increased expression of RHBDD2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:24,091,132...24,102,081
Ensembl chr12:24,092,004...24,102,084
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of RPRM mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:39,595,301...39,596,718
Ensembl chr 3:39,595,301...39,596,718
|
|
G |
S100a7a |
S100 calcium binding protein A7A |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of S100A7A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:190,058,093...190,063,132
Ensembl chr 2:190,058,093...190,062,534
|
|
G |
Scp2 |
sterol carrier protein 2 |
increases expression |
ISO |
Nevirapine results in increased expression of SCP2 |
CTD |
PMID:26626330 |
|
NCBI chr 5:127,647,934...127,735,703
Ensembl chr 5:127,620,274...127,735,739
|
|
G |
Slamf9 |
SLAM family member 9 |
decreases expression |
EXP |
Nevirapine results in decreased expression of SLAMF9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:90,836,419...90,856,913
Ensembl chr13:90,836,361...90,839,411
|
|
G |
Slc34a2 |
solute carrier family 34 member 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr14:60,257,211...60,276,516
Ensembl chr14:60,256,712...60,276,794
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
[Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 protein |
CTD |
PMID:16030158 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression decreases expression |
ISO EXP |
Nevirapine results in increased expression of SREBF1 mRNA Nevirapine metabolite results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21619898 PMID:23947594 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases activity |
EXP |
Nevirapine metabolite results in increased activity of SULT1A1 protein; Nevirapine results in increased activity of SULT1A1 protein |
CTD |
PMID:27417440 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Tg |
thyroglobulin |
increases expression |
ISO |
Nevirapine results in increased expression of TG mRNA; Nevirapine results in increased expression of TG protein |
CTD |
PMID:16030158 |
|
NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
|
|
G |
Tmem159 |
transmembrane protein 159 |
decreases expression |
EXP |
Nevirapine results in decreased expression of TMEM159 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:189,870,596...189,889,485
Ensembl chr 1:189,870,622...189,889,484
|
|
G |
Tmem64 |
transmembrane protein 64 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of TMEM64 mRNA; Nevirapine results in increased expression of TMEM64 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:28,850,864...28,898,203
Ensembl chr 5:28,850,950...28,867,227
|
|
G |
Tox3 |
TOX high mobility group box family member 3 |
increases expression |
EXP |
Nevirapine results in increased expression of TOX3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:18,079,022...18,188,366
Ensembl chr19:18,079,094...18,188,330
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
Nevirapine results in increased expression of TPO mRNA; Nevirapine results in increased expression of TPO protein |
CTD |
PMID:16030158 |
|
NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
|
|
G |
Trim24 |
tripartite motif-containing 24 |
decreases expression |
EXP |
Nevirapine results in decreased expression of TRIM24 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:65,632,278...65,684,746
Ensembl chr 4:65,637,407...65,684,743
|
|
G |
Trim63 |
tripartite motif containing 63 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of TRIM63 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:152,533,362...152,547,138
Ensembl chr 5:152,533,349...152,547,179
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
increases expression |
EXP |
Nevirapine results in increased expression of TSC22D3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:111,884,285...111,944,693
Ensembl chr X:111,884,295...111,887,906
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 protein; Nevirapine promotes the reaction [TSHB protein affects the abundance of Iodine]; sodium perchlorate inhibits the reaction [Nevirapine promotes the reaction [TSHB protein affects the abundance of Iodine]] |
CTD |
PMID:16030158 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
Nevirapine results in increased expression of TSHR mRNA |
CTD |
PMID:16030158 |
|
NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
|
|
G |
Tsku |
tsukushi, small leucine rich proteoglycan |
increases expression |
EXP |
Nevirapine results in increased expression of TSKU mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:163,317,281...163,328,697
Ensembl chr 1:163,317,282...163,328,591
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
Nevirapine results in increased expression of UCP1 |
CTD |
PMID:16038477 |
|
NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
|
|
G |
Ucp3 |
uncoupling protein 3 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of UCP3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:165,482,912...165,495,895
Ensembl chr 1:165,482,155...165,496,206
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of VCAM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Nevirapine results in decreased expression of VEGFA mRNA |
CTD |
PMID:19152342 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vsnl1 |
visinin-like 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of VSNL1 mRNA; Nevirapine results in decreased expression of VSNL1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:37,001,360...37,121,969
Ensembl chr 6:37,001,356...37,122,023
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
increases expression |
EXP |
Nevirapine results in increased expression of ZAP70 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:43,331,149...43,353,097
Ensembl chr 9:43,331,155...43,353,113
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in decreased expression of AKT1 mRNA] |
CTD |
PMID:23308213 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in increased expression of DMP1 mRNA] |
CTD |
PMID:20185895 |
|
NCBI chr14:6,889,851...6,923,961
Ensembl chr14:6,889,856...6,900,733
|
|
G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA] |
CTD |
PMID:18500657 |
|
NCBI chr X:40,460,047...40,717,982
Ensembl chr X:40,460,047...40,717,982
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions increases import |
EXP |
Foscarnet inhibits the reaction [SLC16A1 protein results in increased transport of Benzoic Acid] SLC16A1 protein results in increased import of Foscarnet |
CTD |
PMID:10579682 PMID:10714609 |
|
NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
decreases activity multiple interactions increases expression |
ISO EXP |
Foscarnet results in decreased activity of SLC20A1 protein Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC20A1 mRNA] Foscarnet results in increased expression of SLC20A1 mRNA |
CTD |
PMID:15641067 PMID:17438129 PMID:23308213 |
|
NCBI chr 3:121,725,204...121,739,160
Ensembl chr 3:121,725,859...121,739,173
|
|
G |
Slc20a2 |
solute carrier family 20 member 2 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC20A2 mRNA] |
CTD |
PMID:23308213 |
|
NCBI chr16:74,318,287...74,408,030
Ensembl chr16:74,317,899...74,408,030
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Calcium results in increased expression of SLC23A2 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC23A2 mRNA] |
CTD |
PMID:12788230 |
|
NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Calcium results in increased expression of SPP1 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SPP1 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SPP1 protein] |
CTD |
PMID:12788230 PMID:17383965 PMID:18412142 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Stc1 |
stanniocalcin 1 |
increases expression |
EXP |
Foscarnet results in increased expression of STC1 mRNA |
CTD |
PMID:17438129 |
|
NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Tenofovir results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
affects expression |
ISO |
Tenofovir affects the expression of ACACB mRNA |
CTD |
PMID:20032539 |
|
NCBI chr12:48,127,149...48,238,969
Ensembl chr12:48,127,149...48,238,887
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Tenofovir results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
ISO |
Tenofovir results in increased expression of CCL20 mRNA Tenofovir results in increased expression of and results in increased secretion of CCL20 protein |
CTD |
PMID:24205323 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein Tenofovir results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
Tenofovir results in decreased activity of CYP2C9 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Tenofovir results in decreased activity of CYP2E1 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Edn1 |
endothelin 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of EDN1 protein coenzyme Q10 inhibits the reaction [Tenofovir results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of EIF2S1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of HAVCR1 protein Tenofovir inhibits the reaction [cidofovir results in increased secretion of HAVCR1 protein] |
CTD |
PMID:29738843 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSD11B1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSPD1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects expression |
ISO |
Tenofovir affects the expression of LIPE mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
affects expression |
ISO |
Tenofovir affects the expression of LONP1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:10,428,853...10,441,180
Ensembl chr 9:10,428,853...10,441,177
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of MAPK8 protein |
CTD |
PMID:27041070 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
Tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA] |
CTD |
PMID:16940060 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
EXP |
Tenofovir results in decreased expression of NFKBIA protein |
CTD |
PMID:27899301 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
Tenofovir results in increased expression of NOS2 mRNA; Tenofovir results in increased expression of NOS2 protein |
CTD |
PMID:27899301 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases phosphorylation |
ISO |
coenzyme Q10 inhibits the reaction [Tenofovir results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects expression |
ISO |
Tenofovir affects the expression of NR3C1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Tenofovir results in increased expression of NT5E mRNA |
CTD |
PMID:24205323 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Nt5m |
5',3'-nucleotidase, mitochondrial |
decreases expression |
ISO |
Tenofovir results in decreased expression of NT5M mRNA |
CTD |
PMID:24205323 |
|
NCBI chr10:46,216,494...46,244,478
Ensembl chr10:46,216,884...46,243,077
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression |
ISO |
Tenofovir affects the expression of PPARG mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Tenofovir results in increased expression of PTGS2 mRNA; Tenofovir results in increased expression of PTGS2 protein |
CTD |
PMID:27899301 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization increases expression |
EXP |
Melatonin inhibits the reaction [Tenofovir affects the localization of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of RELA mRNA]; Tenofovir results in increased expression of and results in increased activity of RELA protein |
CTD |
PMID:27899301 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression |
ISO |
Tenofovir results in increased expression of SIRT3 protein |
CTD |
PMID:27041070 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases response to substance increases import multiple interactions |
ISO |
SLC22A6 protein results in increased susceptibility to Tenofovir SLC22A6 protein results in increased import of Tenofovir Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to Tenofovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to Tenofovir; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:23856525 PMID:25448811 PMID:29738843 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases response to substance increases import |
ISO |
SLC22A8 protein results in increased susceptibility to Tenofovir SLC22A8 protein results in increased import of Tenofovir |
CTD |
PMID:25448811 PMID:29738843 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression |
ISO EXP |
Tenofovir results in decreased expression of TNF mRNA Tenofovir results in increased expression of TNF mRNA; Tenofovir results in increased expression of TNF protein |
CTD |
PMID:24205323 PMID:27899301 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein Tenofovir results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[xanthohumol binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; xanthohumol binds to and results in decreased activity of ABCC5 protein; xanthohumol inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of AKT2 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases activity increases expression |
ISO |
xanthohumol results in increased activity of ALPL protein xanthohumol results in increased expression of ALPL mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
xanthohumol inhibits the reaction [Azoxymethane results in decreased expression of BAX protein] |
CTD |
PMID:31714664 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
xanthohumol results in decreased expression of BCL2; xanthohumol results in decreased expression of BCL2 protein xanthohumol inhibits the reaction [Azoxymethane results in increased expression of BCL2 protein] |
CTD |
PMID:15995977 PMID:23562496 PMID:26297991 PMID:31714664 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity increases activity |
ISO EXP |
xanthohumol results in increased cleavage of and results in increased activity of CASP3 protein xanthohumol inhibits the reaction [Azoxymethane results in decreased expression of CASP3 protein] xanthohumol results in decreased activity of CASP3 protein xanthohumol results in increased activity of CASP3 protein |
CTD |
PMID:15995977 PMID:26297991 PMID:27317025 PMID:30240731 PMID:31714664 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
xanthohumol results in increased cleavage of and results in increased activity of CASP7 protein xanthohumol results in increased activity of CASP7 protein |
CTD |
PMID:15995977 PMID:30240731 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
xanthohumol results in increased cleavage of and results in increased activity of CASP8 protein xanthohumol results in increased activity of CASP8 protein |
CTD |
PMID:15995977 PMID:26297991 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
xanthohumol results in increased cleavage of and results in increased activity of CASP9 protein xanthohumol results in increased activity of CASP9 protein |
CTD |
PMID:15995977 PMID:26297991 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; xanthohumol inhibits the reaction [CBR1 protein results in increased reduction of 2,3-hexanedione] |
CTD |
PMID:30849340 |
|
NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO EXP |
xanthohumol results in decreased expression of CCND1 xanthohumol inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein] |
CTD |
PMID:26297991 PMID:27317025 PMID:31714664 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
xanthohumol results in increased expression of CDKN1A |
CTD |
PMID:26297991 PMID:27317025 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Clcn7 |
chloride voltage-gated channel 7 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CLCN7 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr10:14,492,844...14,518,167
Ensembl chr10:14,492,844...14,516,894
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
xanthohumol results in decreased activity of and results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:27317025 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Cryz |
crystallin zeta |
increases activity |
ISO |
xanthohumol results in increased activity of CRYZ protein |
CTD |
PMID:17590382 |
|
NCBI chr 2:260,884,315...260,911,827
Ensembl chr 2:260,884,337...260,911,792
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
xanthohumol inhibits the reaction [Azoxymethane results in decreased phosphorylation of and results in increased activity of CTNNB1 protein] |
CTD |
PMID:31714664 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases expression |
ISO |
xanthohumol promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 mRNA] xanthohumol results in decreased activity of CYP1A1 protein xanthohumol results in increased expression of CYP1A1 mRNA |
CTD |
PMID:22138251 PMID:23503627 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
xanthohumol results in increased expression of CYP1A2 mRNA xanthohumol inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22138251 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
xanthohumol results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
xanthohumol results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gab2 |
GRB2-associated binding protein 2 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of GAB2 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 1:162,082,876...162,283,379
Ensembl chr 1:162,083,030...162,279,727
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases expression multiple interactions |
ISO |
xanthohumol results in decreased expression of GSTA1 mRNA [xanthohumol co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of GSTA1 mRNA |
CTD |
PMID:22138251 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
ISO |
xanthohumol results in increased expression of GSTP1 mRNA; xanthohumol results in increased expression of GSTP1 protein [indole-3-carbinol co-treated with xanthohumol] results in increased expression of GSTP1 mRNA; [phenethyl isothiocyanate co-treated with xanthohumol] results in increased expression of GSTP1 mRNA; [phenethyl isothiocyanate co-treated with xanthohumol] results in increased expression of GSTP1 protein; [Resveratrol co-treated with xanthohumol] results in increased expression of GSTP1 mRNA |
CTD |
PMID:23085367 PMID:32070777 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
xanthohumol results in increased expression of GSTT1 mRNA; xanthohumol results in increased expression of GSTT1 protein |
CTD |
PMID:23085367 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
xanthohumol results in increased expression of HMOX1 mRNA; xanthohumol results in increased expression of HMOX1 protein |
CTD |
PMID:23085367 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
xanthohumol results in decreased expression of ICAM1 protein |
CTD |
PMID:23503627 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [xanthohumol results in increased expression of IL1B protein] |
CTD |
PMID:31629901 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
xanthohumol results in decreased expression of IL6 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation decreases activity |
ISO |
xanthohumol results in decreased phosphorylation of MAPK1 protein xanthohumol results in decreased activity of MAPK1 protein |
CTD |
PMID:26297991 PMID:27317025 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases activity decreases phosphorylation |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of MAPK3 mRNA] xanthohumol results in decreased activity of MAPK3 protein xanthohumol results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:23994090 PMID:26297991 PMID:27317025 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
xanthohumol results in decreased expression of and results in decreased activity of MMP9 protein xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of MMP9 mRNA] xanthohumol results in decreased expression of MMP9 mRNA |
CTD |
PMID:23562496 PMID:23994090 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
xanthohumol inhibits the reaction [Azoxymethane results in increased expression of MYC protein] |
CTD |
PMID:31714664 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions |
ISO |
xanthohumol results in decreased phosphorylation of and results in decreased activity of MYL2 protein |
CTD |
PMID:23503627 |
|
NCBI chr12:39,951,863...39,959,065
Ensembl chr12:39,951,987...39,958,239
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NAT2 mRNA |
CTD |
PMID:22138251 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions increases expression increases activity |
ISO |
xanthohumol affects the localization of NFE2L2 protein [xanthohumol co-treated with phenethyl isothiocyanate] results in increased activity of NFE2L2 protein; [xanthohumol co-treated with phenethyl isothiocyanate] results in increased expression of and results in increased activity of NFE2L2 protein; [xanthohumol co-treated with phenethyl isothiocyanate] results in increased expression of NFE2L2 mRNA; [xanthohumol co-treated with Resveratrol] results in increased expression of NFE2L2 mRNA; [xanthohumol co-treated with Resveratrol] results in increased expression of NFE2L2 protein xanthohumol results in increased expression of NFE2L2 mRNA; xanthohumol results in increased expression of NFE2L2 protein xanthohumol results in increased activity of NFE2L2 protein |
CTD |
PMID:23085367 PMID:32070777 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity decreases expression |
ISO |
[xanthohumol co-treated with phenethyl isothiocyanate] results in decreased expression of and results in decreased activity of NFKB1 protein; [xanthohumol co-treated with phenethyl isothiocyanate] results in decreased expression of NFKB1 mRNA; [xanthohumol co-treated with Resveratrol] results in decreased expression of NFKB1 mRNA xanthohumol results in decreased activity of NFKB1 protein xanthohumol results in decreased expression of NFKB1 mRNA |
CTD |
PMID:32070777 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
xanthohumol inhibits the reaction [Azoxymethane results in increased expression of NOS2 mRNA] |
CTD |
PMID:31714664 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
xanthohumol results in increased expression of NQO1 protein [indole-3-carbinol co-treated with xanthohumol] results in increased expression of NQO1 mRNA; [phenethyl isothiocyanate co-treated with xanthohumol] results in increased expression of NQO1 mRNA; [Resveratrol co-treated with xanthohumol] results in increased expression of NQO1 mRNA; [xanthohumol co-treated with phenethyl isothiocyanate] results in increased expression of NQO1 protein xanthohumol results in increased expression of NQO1 mRNA; xanthohumol results in increased expression of NQO1 protein |
CTD |
PMID:23085367 PMID:26473469 PMID:32070777 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Ostm1 |
osteoclastogenesis associated transmembrane protein 1 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of OSTM1 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr20:47,394,979...47,430,304
Ensembl chr20:47,395,014...47,430,284
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
xanthohumol results in increased cleavage of PARP1 protein |
CTD |
PMID:15995977 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of PIK3CG mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 6:51,465,696...51,501,234
Ensembl chr 6:51,465,908...51,498,337
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases activity multiple interactions decreases expression |
ISO EXP |
xanthohumol results in decreased activity of PTGS2 protein [xanthohumol co-treated with indole-3-carbinol] results in decreased expression of PTGS2 mRNA; [xanthohumol co-treated with phenethyl isothiocyanate] results in decreased expression of PTGS2 mRNA; [xanthohumol co-treated with phenethyl isothiocyanate] results in decreased expression of PTGS2 protein; [xanthohumol co-treated with Resveratrol] results in decreased expression of PTGS2 mRNA xanthohumol results in decreased expression of PTGS2 mRNA xanthohumol inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA] |
CTD |
PMID:17590382 PMID:31714664 PMID:32070777 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pxn |
paxillin |
decreases expression |
ISO |
xanthohumol results in decreased expression of PXN protein |
CTD |
PMID:23503627 |
|
NCBI chr12:46,797,953...46,845,107
Ensembl chr12:46,797,954...46,845,080
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity decreases expression |
ISO |
[indole-3-carbinol co-treated with xanthohumol] results in decreased activity of RELA protein; [indole-3-carbinol co-treated with xanthohumol] results in decreased expression of RELA mRNA; [phenethyl isothiocyanate co-treated with xanthohumol] results in decreased expression of and results in decreased activity of RELA protein; [phenethyl isothiocyanate co-treated with xanthohumol] results in decreased expression of RELA mRNA; [Resveratrol co-treated with xanthohumol] results in decreased activity of RELA protein; [Resveratrol co-treated with xanthohumol] results in decreased expression of RELA mRNA xanthohumol results in decreased activity of RELA protein xanthohumol results in decreased expression of RELA mRNA |
CTD |
PMID:32070777 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
decreases expression |
ISO |
xanthohumol results in decreased expression of S100A4 protein |
CTD |
PMID:23503627 |
|
NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:23503627 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases expression decreases expression |
ISO |
xanthohumol results in increased expression of SULT1A1 mRNA xanthohumol results in decreased expression of SULT1A1 mRNA |
CTD |
PMID:22138251 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Tcirg1 |
T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of TCIRG1 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 1:219,126,687...219,139,466
Ensembl chr 1:219,127,602...219,139,464
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
xanthohumol results in increased expression of TFF1 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:23503627 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases response to substance |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of AKT2 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CLCN7 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of GAB2 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of MAPK3 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of MMP9 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of OSTM1 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of PIK3CG mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of TCIRG1 mRNA]; xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of TRAF6 mRNA] xanthohumol results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:23994090 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
xanthohumol results in increased expression of TP53; xanthohumol results in increased expression of TP53 mRNA; xanthohumol results in increased expression of TP53 protein |
CTD |
PMID:23085367 PMID:26297991 PMID:27317025 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
xanthohumol inhibits the reaction [TNFSF11 protein results in increased expression of TRAF6 mRNA] |
CTD |
PMID:23994090 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions increases expression |
ISO |
xanthohumol promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of UGT1A1 mRNA] xanthohumol results in increased expression of UGT1A1 mRNA |
CTD |
PMID:22138251 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of UGT1A2 mRNA |
CTD |
PMID:22138251 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
xanthohumol results in increased expression of VWF mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:158,085,059...158,219,525
Ensembl chr 4:158,088,505...158,219,523
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
Zalcitabine affects the phosphorylation of AKT1 protein |
CTD |
PMID:19781600 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Zalcitabine binds to ALB protein |
CTD |
PMID:15814459 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ano3 |
anoctamin 3 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ANO3 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 3:101,843,516...102,203,368
Ensembl chr 3:101,840,630...102,151,489
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Zalcitabine |
CTD |
PMID:17259346 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ARNT2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ATP2B4 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr13:50,091,644...50,153,808
Ensembl chr13:50,091,430...50,153,823
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of BPTF mRNA |
CTD |
PMID:18606552 |
|
NCBI chr10:95,248,573...95,350,162
Ensembl chr10:95,250,294...95,349,789
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Zalcitabine results in increased expression of CCL2 protein |
CTD |
PMID:17761732 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
Zalcitabine results in increased expression of CXCL12 mRNA |
CTD |
PMID:17292584 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
Zalcitabine results in increased expression of CXCR4 mRNA |
CTD |
PMID:17292584 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Dck |
deoxycytidine kinase |
affects response to substance |
ISO |
DCK protein affects the susceptibility to Zalcitabine |
CTD |
PMID:11952160 |
|
NCBI chr14:20,935,442...20,952,939
Ensembl chr14:20,935,369...20,953,095
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 2:39,980,796...40,069,982
Ensembl chr 2:40,000,313...40,069,975
|
|
G |
Dlg5 |
discs large MAGUK scaffold protein 5 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of DLG5 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr15:120,213...230,312
Ensembl chr15:120,372...228,977
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ESRRG mRNA |
CTD |
PMID:18606552 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Fam81a |
family with sequence similarity 81, member A |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of FAM81A mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 8:76,521,662...76,579,387
Ensembl chr 8:76,521,657...76,579,387
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of FPGT mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 2:261,382,015...261,402,950
Ensembl chr 2:261,382,060...261,402,903
|
|
G |
Gla |
galactosidase, alpha |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of GLA mRNA |
CTD |
PMID:18606552 |
|
NCBI chr X:105,405,915...105,417,331
Ensembl chr X:105,406,792...105,417,323
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
increases response to substance increases expression multiple interactions |
ISO EXP |
HTR2A gene results in increased susceptibility to Zalcitabine Zalcitabine results in increased expression of HTR2A protein [alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Zalcitabine |
CTD |
PMID:17888573 |
|
NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression multiple interactions |
ISO |
Zalcitabine results in decreased expression of IL2RA mRNA; Zalcitabine results in decreased expression of IL2RA protein Zidovudine promotes the reaction [Zalcitabine results in decreased expression of IL2RA mRNA]; Zidovudine promotes the reaction [Zalcitabine results in decreased expression of IL2RA protein] |
CTD |
PMID:7606800 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of IRF7 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of KIF5A mRNA |
CTD |
| |